Defining intermediate-risk prostate cancer suitable for active surveillance with PSA 10-20ng/ml: Pathological outcome analysis of a population-level dataset

• P.E. Lonergan,
• C.W. Jeong,
• S.L. Washington,
• A. Herlemann,
• P.R. Carroll,
• M.R. Cooperberg

Affiliations

P.E. Lonergan

C.W. Jeong

S.L. Washington

A. Herlemann

P.R. Carroll

M.R. Cooperberg